Parabolic Drugs

parabolicdrugs.com

Parabolic Drugs Limited is a vertically integrated, research based, Pharmaceutical manufacturer and exporter, specializing in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates. The Company has dedicated facilities for Custom Research and API manufacturing at its 4 locations, 2 in Haryana (India) and 2 in Punjab (India) and exporting to over 51 countries across the globe from its WHO-GMP facilities. Parabolic has a wide Product basket, ranging from Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, NSAID, Anti-Hypertensive and Osteoporosis segments.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

news image

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More

BUSINESS INSIGHTS

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

news image

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More

PHARMACY MARKET

VIVERA PARTNERS WITH NINDS OF NIH TO IDENTIFY POTENTIAL STUTTERING TREATMENTS

Vivera Pharmaceuticals, Inc. | May 18, 2022

news image

Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. Th...

Read More

BUSINESS INSIGHTS

FUISZ PHARMA LLC RECEIVES A PATENT FOR A NON-INVASIVE UROLOGICAL DEVICE TO TREAT BENIGN PROSTATE HYPERPLASIA SYMPTOMS (BPH)

FUISZ LLC | April 19, 2022

news image

The first patent for Fuisz Pharma LLC's non-invasive urological device platform to alleviate symptoms of BPH, US 11,213,41, entitled "Device and Method for Reducing Urinary Retention," was issued via Fuisz LLC. Fuisz Pharma LLC is still looking for additional patent protection to go along with the one that was obtained. The Fuisz device is non-invasive, simple to use, and has been shown to help initiate urination, minimize dribbling and nocturia, and decrease urine r...

Read More
news image

PHARMACY MARKET

BOSTON SCIENTIFIC ANNOUNCES PARTNERSHIP DEFINITIVE AGREEMENT TO DIVEST BTG SPECIALTY PHARMACEUTICALS BUSINESS

Boston Scientific | December 02, 2020

Boston Scientific Corporation today declared that it has gone into a conclusive concurrence with Stark International Lux S.A.R.L., and SERB SAS, partners of SERB, an European strength drug gathering, to sell its BTG Specialty Pharmaceuticals business for $800 million in real money. SERB, supported by private value firm Charterhouse Capital Partners since 2017, possesses an expanded arrangement of doctor prescribed prescriptions zeroed in on uncommon and hazardous infections. "...

Read More
news image

BUSINESS INSIGHTS

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More
news image

PHARMACY MARKET

VIVERA PARTNERS WITH NINDS OF NIH TO IDENTIFY POTENTIAL STUTTERING TREATMENTS

Vivera Pharmaceuticals, Inc. | May 18, 2022

Vivera Biosciences, a division of Vivera Pharmaceuticals dedicated to the research and development of innovative medical technologies and pharmaceutical therapies, is pleased to announce its collaborative progress on a Cooperative Research and Development Agreement with the National Institute of Neurological Disorders and Stroke an Institute within the National Institutes of Health that aims to foster and advance cutting-edge neuroscience research to reduce the burden of neurological disease. Th...

Read More
news image

BUSINESS INSIGHTS

FUISZ PHARMA LLC RECEIVES A PATENT FOR A NON-INVASIVE UROLOGICAL DEVICE TO TREAT BENIGN PROSTATE HYPERPLASIA SYMPTOMS (BPH)

FUISZ LLC | April 19, 2022

The first patent for Fuisz Pharma LLC's non-invasive urological device platform to alleviate symptoms of BPH, US 11,213,41, entitled "Device and Method for Reducing Urinary Retention," was issued via Fuisz LLC. Fuisz Pharma LLC is still looking for additional patent protection to go along with the one that was obtained. The Fuisz device is non-invasive, simple to use, and has been shown to help initiate urination, minimize dribbling and nocturia, and decrease urine r...

Read More